Compugen Discloses Successful Validation Results For Novel B7/CD28–like Cancer Immunotherapy Target Candidate

By: via Benzinga
Compugen Ltd. (NASDAQ: CGEN) today disclosed successful experimental data for CGEN-15027, a Compugen-discovered immune checkpoint ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.